论文部分内容阅读
建立体外诱导分化骨髓来源树突状细胞(dendritic cell,DC)疫苗激活抗小鼠黑色素瘤CTL反应模型。体外分化小鼠骨髓来源树突状细胞并荷载鸡卵清白蛋白OVA257-264,静脉免疫小鼠1周之后接种表达OVA全长蛋白的小鼠黑色素瘤B16,观察成瘤情况并评价免疫效果。结果,体外分化小鼠骨髓来源树突状细胞并荷载OVA257-264肽段,表面表达肽段-主要组织相容性复合物(pMHC)作为第一信号以及共刺激分子CD80以及CD40;体内成瘤实验显示,静脉注射荷载OVA257-264能够抵抗B16-OVA的成瘤。DC疫苗静脉免疫后主要分布于肺部和脾脏。本研究通过静脉注射荷载OVA257-264肽段成熟DC,成功的诱导小鼠CTL免疫反应,抵抗黑色素瘤的成瘤。
A dendritic cell (DC) vaccine derived from differentiated bone marrow was established to induce anti-mouse melanoma CTL response in vitro. The mouse bone marrow-derived dendritic cells were differentiated in vitro and ovalbumin OVA257-264 was loaded. One week later, mice were inoculated with mouse melanoma B16 expressing OVA full-length protein. The tumorigenicity was observed and the immune effect was evaluated. RESULTS: Bone marrow-derived dendritic cells were differentiated in vitro and loaded with peptide OVA257-264, surface-expressed peptide-major histocompatibility complex (pMHC) as the first signal and co-stimulatory molecules CD80 and CD40; in vivo tumorigenesis Experiments show that intravenous injection of OVA257-264 can resist B16-OVA tumor formation. DC vaccine is mainly distributed in the lungs and spleen after intravenous immunization. In this study, OVA257-264 peptide mature DCs were injected intravenously to induce the CTL immune response in mice and resist the tumorigenesis of melanoma.